BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31968702)

  • 1. Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.
    Li E; Yan F; Huang P; Chi H; Xu S; Li G; Liu C; Feng N; Wang H; Zhao Y; Yang S; Xia X
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31968702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice.
    Li E; Chi H; Huang P; Yan F; Zhang Y; Liu C; Wang Z; Li G; Zhang S; Mo R; Jin H; Wang H; Feng N; Wang J; Bi Y; Wang T; Sun W; Gao Y; Zhao Y; Yang S; Xia X
    Viruses; 2019 Aug; 11(9):. PubMed ID: 31470645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
    Wirblich C; Coleman CM; Kurup D; Abraham TS; Bernbaum JG; Jahrling PB; Hensley LE; Johnson RF; Frieman MB; Schnell MJ
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
    Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
    PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
    Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
    Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection.
    Jia W; Channappanavar R; Zhang C; Li M; Zhou H; Zhang S; Zhou P; Xu J; Shan S; Shi X; Wang X; Zhao J; Zhou D; Perlman S; Zhang L
    Emerg Microbes Infect; 2019; 8(1):760-772. PubMed ID: 31130102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
    Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
    Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
    Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK
    J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
    Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
    Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV.
    Almansour I; Jermy BR
    Hum Vaccin Immunother; 2024 Dec; 20(1):2346390. PubMed ID: 38691025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated Rabies Virus Vectored MERS-Coronavirus Vaccine Induces Protective Immunity in Mice, Camels, and Alpacas.
    Chi H; Wang Y; Li E; Wang X; Wang H; Jin H; Han Q; Wang Z; Wang X; Zhu A; Sun J; Zhuang Z; Zhang L; Ye J; Wang H; Feng N; Hu M; Gao Y; Zhao J; Zhao Y; Yang S; Xia X
    Front Immunol; 2022; 13():823949. PubMed ID: 35173733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
    Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
    Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
    Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
    Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.
    Guo X; Deng Y; Chen H; Lan J; Wang W; Zou X; Hung T; Lu Z; Tan W
    Immunology; 2015 Aug; 145(4):476-84. PubMed ID: 25762305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
    Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
    Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.